TruScreen Q3 FY2024 Sales Growth Report

TruScreen Group Limited (ASX: $TRU) has announced a 40% growth in sales of devices and a 22% growth in sales of Single Disposable Sensor (SUS) for the nine months to 31 December 2023. The company's revenues YTD to 31 December 2023 reached USD $887,958.00 (NZD$1,465,131), marking a 34% increase on the prior year. China has been a major contributor to this growth following recognition of TruScreen in the major national Guidelines by the Chinese Society of Colposcopy and Cervical Pathology (CSCCP). Additionally, the successful Zimbabwe screening program under the National Aids Council has screened a total of 14,000 women in Masvingo province to date, with plans for expansion beyond Masvingo province in financial year 2025.

Executive Commentary on Q3 FY2024 Results

Dr Beata Edling, CEO of TruScreen Group Limited, expressed delight in reporting the Q3 FY2024 results. She congratulated the partner, SWXT, for achieving strong growth in China and emphasized the company's continued collaboration with the National AIDS Council of Ministry of Health in Zimbabwe to advance the successful point-of-care program in Masvingo Province.

Summary of TruScreen Q3 FY2024 Announcement

TruScreen Group Limited (ASX: $TRU) has reported a significant increase in sales of devices and Single Disposable Sensor (SUS) for the nine months to 31 December 2023, driven by strong growth in China and the successful Zimbabwe screening program. The company's vision of 'A world without cervical cancer' aligns with its continuous efforts to expand its screening technology and make a positive impact in the fight against cervical cancer. With the anticipation of program expansion beyond Masvingo province in financial year 2025, TruScreen remains committed to advancing its point-of-care program and contributing to global cervical cancer prevention efforts.